1. Home
  2. TVTX vs NAD Comparison

TVTX vs NAD Comparison

Compare TVTX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • NAD
  • Stock Information
  • Founded
  • TVTX 2008
  • NAD 1999
  • Country
  • TVTX United States
  • NAD United States
  • Employees
  • TVTX 385
  • NAD N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • NAD Investment Managers
  • Sector
  • TVTX Health Care
  • NAD Finance
  • Exchange
  • TVTX Nasdaq
  • NAD Nasdaq
  • Market Cap
  • TVTX 3.1B
  • NAD 2.8B
  • IPO Year
  • TVTX N/A
  • NAD N/A
  • Fundamental
  • Price
  • TVTX $33.95
  • NAD $11.95
  • Analyst Decision
  • TVTX Strong Buy
  • NAD
  • Analyst Count
  • TVTX 15
  • NAD 0
  • Target Price
  • TVTX $37.21
  • NAD N/A
  • AVG Volume (30 Days)
  • TVTX 2.1M
  • NAD 595.7K
  • Earning Date
  • TVTX 10-30-2025
  • NAD 01-01-0001
  • Dividend Yield
  • TVTX N/A
  • NAD 4.35%
  • EPS Growth
  • TVTX N/A
  • NAD N/A
  • EPS
  • TVTX N/A
  • NAD N/A
  • Revenue
  • TVTX $435,826,000.00
  • NAD N/A
  • Revenue This Year
  • TVTX $108.68
  • NAD N/A
  • Revenue Next Year
  • TVTX $40.23
  • NAD N/A
  • P/E Ratio
  • TVTX N/A
  • NAD N/A
  • Revenue Growth
  • TVTX 114.22
  • NAD N/A
  • 52 Week Low
  • TVTX $12.91
  • NAD $9.56
  • 52 Week High
  • TVTX $36.15
  • NAD $11.64
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 76.66
  • NAD 60.43
  • Support Level
  • TVTX $26.79
  • NAD $11.92
  • Resistance Level
  • TVTX $36.15
  • NAD $12.03
  • Average True Range (ATR)
  • TVTX 1.41
  • NAD 0.08
  • MACD
  • TVTX 0.46
  • NAD -0.00
  • Stochastic Oscillator
  • TVTX 76.44
  • NAD 74.60

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About NAD Nuveen Quality Municipal Income Fund

Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: